### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

# **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier		√
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.		<b>√</b>
Provide accession number in repository <b>OR</b>		
supplier name, catalog number, clone number,		
<b>OR</b> RRID		
Primary cultures: Provide species, strain, sex of		√
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		<b>√</b>
genetic modification status. Provide accession		-
number in repository <b>OR</b> supplier name, catalog		
number, clone number, <b>OR</b> RRID		
Animal observed in or captured from the		<b>√</b>
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number		<b>√</b>
in repository (where relevant) OR RRID		-

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		√
<b>Microbes:</b> provide species and strain, unique accession number if available, and source		√

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or		√
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent		√
obtained from study participants.		
Report on age and sex for all study participants.		$\sqrt{}$

## **Design**

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.		√
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.		√
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, <b>or</b> if they were not carried out.	, , , , , , , , , , , , , , , , , , , ,	
Sample size determination		√
Randomisation		√
Blinding Inclusion/exclusion criteria		√ √
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory		V
Define whether data describe technical or biological		V
replicates		•
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		<b>√</b>
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		<b>√</b>
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	All of the procedures were conducted conforming to the guidelines approved by Institutional Ethics Committee at Fudan University Shanghai Cancer Center. (Page 5, line 3-5)	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		√

## **Analysis**

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is		С
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Yes (Page 6, line 8-10).	
tests.		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,		√
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession		√
number in repository or DOI or URL.		
If publicly available data are reused, provide		√
accession number in repository or DOI or URL, where		
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.		√
If code is publicly available, provide accession		√
number in repository, or DOI or URL.		

# Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	We have followed relevant discipline-specific	
ARRIVE) have been followed, and whether a checklist	guidelines for the medical study.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with	ICMJE guidelines were followed, as the journal follows	
the manuscript.	ICMJE recommendations for publication.	

 $Article\ information:\ https://dx.doi.org/10.21037/atm-21-4235$